Christopher Thomas Giordano - 09 Jun 2022 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
CEO, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
09 Jun 2022
Net transactions value
$0
Form type
4
Filing time
10 Jun 2022, 21:15:02 UTC
Previous filing
15 Jul 2021
Next filing
21 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 09 Jun 2022 Common Stock 200,000 $0.6200 Direct F1
holding TENX Stock Option (right to buy) 250,000 09 Jun 2022 Common Stock 250,000 $1.97 Direct F2
holding TENX Stock Option (right to buy) 100,000 09 Jun 2022 Common Stock 100,000 $1.97 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable as follows: options with respect to 50,000 underlying shares of Common Stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F2 The options vest and become exercisable as follows: options with respect to 62,500 underlying shares of Common Stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
F3 The options vest in two tranches upon achievement of certain performance metrics: 50% upon initiation of a Phase 3 trial for levosimendan by June 30, 2022; and 50% upon initiation of a Phase 3 trial for imatinib by June 30, 2022, subject to the Reporting Person's continued employment.